<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00509717</url>
  </required_header>
  <id_info>
    <org_study_id>WOK/WINAp/CZ-02</org_study_id>
    <nct_id>NCT00509717</nct_id>
  </id_info>
  <brief_title>Implementation of a Pharmacy-Intervention to Enhance Prescription and Use of Lipid-Lowering Drugs</brief_title>
  <official_title>Implementation of a Pharmacy-Intervention to Enhance Prescription and Use of Lipid-Lowering Drugs. A Randomized Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zorgverzekeraar CZ</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scientific Institute for Dutch Pharmacists, The Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of maximal support of community
      pharmacies to implement a pharmaceutical care model for improving underprescription and
      treatment persistence regarding lipid-lowering medication in patients with cardiovascular
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease is the main cause of death in large parts of the world. Next to life
      style changes, pharmaceutical treatment is a keystone in the treatment of cardiovascular
      disease. Despite the strong evidence for the effectiveness of lipid-lowering therapy, less
      than half of the people eligible are treated. With specific medication searches in the
      community pharmacy database, an easy tool for detecting patients who are undertreated is
      available. Based on this tool, a pharmaceutical care model for improving underprescription
      and treatment persistence regarding lipid-lowering medication in patients with cardiovascular
      disease was constructed.

      Moreover, it is not known yet how to implement this pharmaceutical care model in community
      pharmacies effectively. With multifaceted interventions the behaviour of health professionals
      can be changed. In this study the effectiveness of a maximal support strategy, including
      interactive educational meetings, reminders, audit and feedback, is compared to a minimal
      implementation strategy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of selected (=undertreated) patients receiving at least one prescription for lipid-lowering medication.</measure>
    <time_frame>six months after the general practitioner received the list with selected patients</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in prescribing for age categories and co-medication.</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>intensive implementation programme</intervention_name>
    <description>educational manual; interactive educational meeting tailored to individual needs; reminders and feedback by 3 newsletters and at least 3 telephone calls.</description>
    <arm_group_label>experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control</intervention_name>
    <description>educational manual</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pharmacies: resident in the south of the Netherlands

          -  patients: with antiplatelet therapy and without lipid-lowering medication

        Exclusion Criteria:for patients:

          -  terminal disease

          -  severe mental disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter G. de Smet, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel Wensing, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Scientific Institute for Quality of Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMC St Radboud, Scientific Institute for Quality of Healthcare</name>
      <address>
        <city>Nijmegen</city>
        <state>NL</state>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Mantel-Teeuwisse AK, Verschuren WM, Klungel OH, de Boer A, Kromhout D. Recent trends in (under)treatment of hypercholesterolaemia in the Netherlands. Br J Clin Pharmacol. 2004 Sep;58(3):310-6.</citation>
    <PMID>15327591</PMID>
  </reference>
  <reference>
    <citation>Blenkinsopp A, Anderson C, Armstrong M. Systematic review of the effectiveness of community pharmacy-based interventions to reduce risk behaviours and risk factors for coronary heart disease. J Public Health Med. 2003 Jun;25(2):144-53. Review.</citation>
    <PMID>12848404</PMID>
  </reference>
  <reference>
    <citation>Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, Whitty P, Eccles MP, Matowe L, Shirran L, Wensing M, Dijkstra R, Donaldson C. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess. 2004 Feb;8(6):iii-iv, 1-72. Review.</citation>
    <PMID>14960256</PMID>
  </reference>
  <reference>
    <citation>Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 Jul 6;360(9326):7-22.</citation>
    <PMID>12114036</PMID>
  </reference>
  <reference>
    <citation>Gaw A. The care gap: underuse of statin therapy in the elderly. Int J Clin Pract. 2004 Aug;58(8):777-85. Review.</citation>
    <PMID>15372851</PMID>
  </reference>
  <reference>
    <citation>Teeling M, Bennett K, Feely J. The influence of guidelines on the use of statins: analysis of prescribing trends 1998-2002. Br J Clin Pharmacol. 2005 Feb;59(2):227-32.</citation>
    <PMID>15676046</PMID>
  </reference>
  <reference>
    <citation>van Wyk JT, Picelli G, Dieleman JP, Mozaffari E, Kramarz P, van Wijk MA, van der Lei J, Sturkenboom MC. Management of hypertension and hypercholesterolaemia in primary care in The Netherlands. Curr Med Res Opin. 2005 Jun;21(6):839-48.</citation>
    <PMID>15969884</PMID>
  </reference>
  <reference>
    <citation>Nederlands Huisartsen Genootschap (NHG). NHG-standaard Cardiovasculair Risicomanagement. 2006 Jan.</citation>
  </reference>
  <reference>
    <citation>Stuurman-Bieze AG, de Boer WO, Kokenberg ME, Hugtenburg JG, de Jong-van den Berg LT, Tromp TF. Complex pharmaceutical care intervention in pulmonary care: part A. The process and pharmacists' professional satisfaction. Pharm World Sci. 2005 Oct;27(5):376-84.</citation>
    <PMID>16341744</PMID>
  </reference>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2007</study_first_submitted>
  <study_first_submitted_qc>July 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2007</study_first_posted>
  <last_update_submitted>July 9, 2008</last_update_submitted>
  <last_update_submitted_qc>July 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>Caroline van de Steeg-van Gompel</name_title>
    <organization>Scientific Institute for Quality of Healthcare</organization>
  </responsible_party>
  <keyword>quality of health care</keyword>
  <keyword>prescriptions, drug</keyword>
  <keyword>anticholesteremic agents</keyword>
  <keyword>community pharmacy services</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypolipidemic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

